



8th February, 2022

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400051

Corporate Office :
406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
Fax : 079-26588054
CIN No. : L24231GJ2004PLC043861
E-mail : info@sakarhealthcare.com
Web : www.sakarhealthcare.com

Dear Sir,

**Sub: Outcome of Board Meeting and Submission of Unaudited Financial Results & Limited Review Reports
(Standalone & Consolidated) for the quarter ended on 31st December, 2021**

We refer to our letter dated 31st January, 2022 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended on 31st December, 2021. These results have been reviewed by the Statutory Auditors of the Company and they have provided their limited review reports dated 8th February, 2022.


We are enclosing herewith copy of the said Unaudited Financial Results and Limited Review Reports.

This is as per Regulation – 30 and 33 of the SEBI (LODR) Regulations, 2015.

Thanking you.

Yours faithfully,

for **SAKAR HEALTHCARE LIMITED**


SANJAY S. SHAH
MANAGING DIRECTOR
(DIN : 01515296)



Encl: As above.

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 31ST DECEMBER, 2021

(Rs. In lakh)

Particulars		Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on
		31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	31-03-2021
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	2974.04	3,164.10	2,679.34	9163.93	7,305.79	9,473.93
2	Other income	26.83	74.79	26.60	128.71	76.16	117.53
3	Total Income (1+2)	3000.87	3,238.89	2,705.94	9292.64	7,381.95	9,591.46
4	Expenses						
	a. Cost of Materials consumed	1696.08	1,931.50	1,696.51	5309.05	4,132.17	5,201.87
	b. Purchases of stock-in-trade	-	-	-	-	-	-
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	13.09	33.07	76.32	107.96	101.38	(90.63)
	d. Employee benefits expense	335.80	332.13	354.55	990.03	1,006.17	1,325.51
	e. Finance costs	94.33	78.89	79.81	221.92	204.83	248.25
	f. Depreciation & amortisation expense (Note No. 9)	261.68	167.56	107.67	647.27	324.30	805.83
	g. Other expenses	263.97	158.39	166.12	734.43	512.50	776.41
	Total Expenses	2664.95	2,701.54	2,480.98	8010.66	6,281.35	8,267.24
5	Profit before exceptional items and tax (3-4)	335.92	537.35	224.96	1281.98	1,100.60	1,324.22
6	Exceptional items	-	-	-	-	-	-
7	Profit before tax (5+6)	335.92	537.35	224.96	1281.98	1,100.60	1,324.22
8	Tax expense:						
	Current tax (Note No. 10)	(38.54)	135.12	39.51	167.99	283.16	317.75
	Deferred tax (Note No. 11)	363.16	155.79	5.50	490.81	(77.36)	(62.73)
9	Profit for the period from continuing operations (7-8)	11.30	246.44	179.95	623.18	894.80	1,069.20
10	Profit from discontinuing operations before Tax	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	Profit for the period (9+12)	11.30	246.44	179.95	623.18	894.80	1,069.20



Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

Particulars		Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on 31-03-2021
		31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
14	Other Comprehensive Income						
	<i>Items that will not be reclassified subsequently to profit or loss</i>						
	Re-measurement gains/(losses) on defined benefit plans	1.61	1.61	(1.46)	4.82	(4.38)	6.43
	Income tax relating to items that will not be reclassified to profit or loss	(0.47)	(1.40)	0.41	(1.40)	1.22	(1.79)
	<i>Items that will be reclassified subsequently to profit or loss</i>						
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Other Comprehensive Income, net of tax	1.14	0.21	(1.05)	3.42	(3.16)	4.64
15	Total Comprehensive Income for the period (13+14)	12.44	246.65	178.90	626.60	891.64	1,073.84
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	1711.80	1711.80	1496.10	1711.80	1496.10	1,561.80
17	Reserves excluding Revaluation Reserves			-		-	8284.37
18	Earnings Per Share of Rs. 10/- each (for continuing operations)						
	- Basic	0.07	1.44	1.20	3.66	5.96	6.88
	- Diluted	0.07	1.44	1.20	3.66	5.96	6.88
19	Earnings Per Share of Rs. 10/- each (for discontinued operations)						
	- Basic	-	-	-	-	-	-
	- Diluted	-	-	-	-	-	-
20	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)						
	- Basic	0.07	1.44	1.20	3.66	5.96	6.88
	- Diluted	0.07	1.44	1.20	3.66	5.96	6.88



Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

Notes:

1	The Company is operating only in one segment. Hence segment reporting is not given.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
3	The Company has a wholly owned subsidiary vis. M/s. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/ associate.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. Due care has been exercised, in concluding on significant accounting judgments and estimates, including in relation to recoverability of receivables, assessment of impairment of intangibles, investments and inventory, based on the information available to date, while preparing the Company's financial results as of and for the quarter ended 31 st December, 2021
7	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 8 th February, 2022
8	We are glad to inform all the stakeholders that Sakar Healthcare Inaugurates in October 2021 Research Laboratories (R&D, F& D, ADL)- part of fully integrated Anti- Cancer API & Finished Dosage Formulation Manufacturing Unit setup at Bavla, Ahmedabad. With the initiation of commercial operations the fixed assets base of the company have increased to the extent of the new manufacturing plant resulting into incremental amount of depreciation being charged to the profit and loss account during the current quarter compared to the earlier quarter leading to comparatively lower Net profit though the Operating profit before interest, depreciation, tax and amortization is in line to earlier period.
9	During the quarter ended on December 21, the amount of depreciation and amortisation expenses Rs. 261.68 lakhs has been charged to profit and loss account compared to Rs. 167.56 lakhs charged in the quarter ended on september 21, the incremental charge is on account of capitalisation of fixed assets pertaining to the new oncology manufacturing plant at Bavla Ahmedabad commercialised from October 2021.
10	During the quarter ended on December 21, the company has reduced the amount of provision for income tax expense by Rs. 38.54 lakhs compared to the quarter ended on september 21, on account of reduction in the estimated amount of profit taxable under income tax resulting from incremental charge of depreciation estimated for the year.
11	During the quarter ended on December 21, the company has increased the amount of provision for deferred tax expense compared to the quarter ended on september 21, as required and stipulated by the statutory provisions of companies act and income tax act.

Date: 8th February, 2022
Place: Ahmedabad

for SAKAR HEALTHCARE LIMITED



Sanjay S. Shah
SANJAY S. SHAH
MANAGING DIRECTOR
(DIN : 01515296)

Corporate Office: 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007
Phone: 079-26584655 Fax: 079-26588054



A. L. Thakkar & Co.
Chartered Accountants

Ahmedabad Office :

603-607, Aarya Epoch, Opp. Passport Seva Kendra,
Nr. Vijay Cross Roads, Navrangpura, Ahmedabad-380 009.

A. L. THAKKAR
B.Com., L.L.B., F.C.A.

S. V. SHAH
B.Com., F.C.A.

M.: 99780 34283, 70160 64684 • **Ph.:** (079) 48940856

E-mail : info@althakkar.com • **Website :** www.althakkar.com

LIMITED REVIEW REPORT

Review Report to the Board of Directors of SAKAR HEALTHCARE LIMITED.

We have reviewed the accompanying statement of unaudited standalone financial results of **SAKAR HEALTHCARE LIMITED** for the period ended **31st December, 2021** ("the statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For A.L.Thakkar & Co
Chartered Accountants
FRN 120116W

Sanjiv Shah
Partner

Place: ahmedabad
Date: 08.02.2022

Membership No. : 042264
UDIN : 22042264AAUOPF1036

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED ON 31ST DECEMBER, 2021

(Rs. In lakh)

Particulars		Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on 31-03-2021
		31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	2974.04	3,164.10	2,679.34	9163.93	7,305.79	9,473.93
2	Other income	26.83	74.79	26.60	128.71	76.16	117.53
3	Total Income (1+2)	3000.87	3,238.89	2,705.94	9292.64	7,381.95	9,591.46
4	Expenses						
	h. Cost of Materials consumed	1696.08	1,931.50	1,696.51	5309.05	4,132.17	5,201.87
	i. Purchases of stock-in-trade	-	-	-	-	-	-
	j. Changes in inventories of finished goods, work-in-progress and stock-in-trade	13.09	33.07	76.32	107.96	101.38	(90.63)
	k. Employee benefits expense	335.80	332.13	354.55	990.03	1,006.32	1,326.46
	l. Finance costs	94.33	78.89	79.81	221.92	204.83	248.25
	m. Depreciation & amortisation expense (Note No. 9)	261.68	167.56	107.67	647.26	324.30	805.83
	n. Other expenses	263.97	158.39	166.12	734.43	512.50	776.41
	Total Expenses	2664.95	2,701.54	2,480.98	8010.66	6,281.50	8,268.19
5	Profit before exceptional items and tax (3-4)	335.92	537.35	224.96	1281.98	1,100.45	1,323.27
6	Exceptional items	-	-	-	-	-	-
7	Profit before tax (5-6)	335.92	537.35	224.96	1281.98	1,100.45	1,323.27
8	Tax expense:						
	Current tax (Note No. 10)	(38.54)	135.12	39.51	167.99	283.15	317.75
	Deferred tax (Note No. 11)	363.16	155.79	5.50	490.81	(77.36)	(62.73)
9	Profit for the period from continuing operations (7-8)	11.30	246.44	179.95	623.18	894.66	1,068.25
10	Profit from discontinuing operations before Tax	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	Share of profit of associates and joint ventures accounted for using equity method	-	-	-	-	-	-
14	Profit for the period (9+12+13)	11.30	246.44	179.95	623.18	894.66	1,068.25
	Attributable to owner of parent	11.30	246.44	179.95	623.18	894.66	1,068.25
	Attributable to Non-controlling interests	-	-	-	-	-	-

Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

Particulars		Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on 31-03-2021
(Refer Notes Below)		31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	(Audited)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
15	Other Comprehensive Income						
	<i>Items that will not be reclassified subsequently to profit or loss</i>						
	Re-measurement gains/(losses) on defined benefit plans	1.61	1.61	(1.46)	4.82	(4.38)	6.43
	Income tax relating to items that will not be reclassified to profit or loss	(0.47)	(1.40)	0.41	(1.40)	1.22	(1.79)
	<i>Items that will be reclassified subsequently to profit or loss</i>						
	Income tax relating to items that will be reclassified to profit or loss				-	-	-
	Other Comprehensive Income, net of tax	1.14	0.21	(1.05)	3.42	(3.16)	4.64
	Attributable to owner of parent	1.14	0.21	(1.05)	3.42	(3.16)	4.64
	Attributable to Non-controlling interests			-		-	-
16	Total Comprehensive Income for the period (14+15)	12.44	246.65	178.90	626.60	891.50	1,072.89
	Attributable to owner of parent	12.44	246.65	178.90	626.60	891.50	1,072.89
	Attributable to Non-controlling interests					-	-
17	Paid-up equity shares capital (Face Value per share Rs. 10/-)	1711.80	1711.80	1496.10	1711.80	1,496.10	1,561.80
18	Reserves excluding Revaluation Reserves						8,283.42
19	Earnings Per Share of Rs. 10/- each (for continuing operations)						
	- Basic	0.07	1.44	1.20	3.66	5.96	6.87
	- Diluted	0.07	1.44	1.20	3.66	5.96	6.87
20	Earnings Per Share of Rs. 10/- each (for discontinued operations)						
	- Basic				-	-	-
	- Diluted				-	-	-
21	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)						
	- Basic	0.07	1.44	1.20	3.66	5.96	6.87
	- Diluted	0.07	1.44	1.20	3.66	5.96	6.87



Corporate Office: 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007
Phone: 079-26584655 Fax: 079-26588054

Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213


Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

Notes:

1	The Company is operating only in one segment. Hence segment reporting is not given.
2	The consolidated Unaudited financial results of the Company are comprising of its subsidiary M/s. Sakar Oncology Private Limited.
3	The Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 “Interim Financial Reporting” as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics. Due care has been exercised, in concluding on significant accounting judgments and estimates, including in relation to recoverability of receivables, assessment of impairment of intangibles, investments and inventory, based on the information available to date, while preparing the Company’s financial results as of and for the quarter ended 31 st December, 2021
7	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 8 th February, 2022
8	We are glad to inform all the stakeholders that Sakar Healthcare Inaugurates in October 2021 Research Laboratories (R & D F& D, ADL)- part of fully integrated Anti- Cancer API & Finished Dosage Formulation Manufacturing Unit setup at Bavla, Ahmedabad. With the initiation of commercial operations the fixed assets base of the company have increased to the extent of the new manufacturing plant resulting into incremental amount of depreciation being charged to the profit and loss account during the current quarter compared to the earlier quarter leading to comparatively lower Net profit though the Operating profit before interest, depreciation, tax and amortization is in line to earlier period.
9	During the quarter ended on December 21, the amount of depreciation and amortisation expenses Rs. 261.68 lakhs has been charged to profit and loss account compared to Rs. 167.56 lakhs charged in the quarter ended on september 21, the incremental charge is on account of capitalisation of fixed assets pertaining to the new oncology manufacturing plant at Bavla Ahmedabad commercialised from October 2021.
10	During the quarter ended on December 21, the company has reduced the amount of provision for income tax expense by Rs. 38.54 lakhs compared to the quarter ended on september 21, on account of reduction in the estimated amount of profit taxable under income tax resulting from incremental charge of depreciation estimated for the year.
11	During the quarter ended on December 21, the company has increased the amount of provision for deferred tax expense compared to the quarter ended on september 21, as required and stipulated by the statutory provisions of companies act and income tax act.

for SAKAR HEALTHCARE LIMITED




SANJAY S. SHAH
MANAGING DIRECTOR
(DIN : 01515296)

Date: 8th February, 2022
Place: Ahmedabad



A. L. Thakkar & Co.
Chartered Accountants

A. L. THAKKAR
B.Com., L.L.B., F.C.A.

S. V. SHAH
B.Com., F.C.A.

Ahmedabad Office :

603-607, Aarya Epoch, Opp. Passport Seva Kendra,
Nr. Vijay Cross Roads, Navrangpura, Ahmedabad-380 009.

M.: 99780 34283, 70160 84684

E-mail : info@althakkar.com

Ph.: (079) 48940856

Website : www.althakkar.com

CONSOLIDATED LRR REPORT

TO THE BOARD OF DIRECTORS OF SAKAR HEALTHCARE LIMITED

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **SAKAR HEALTHCARE LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/ (loss) after tax and total comprehensive income / loss of its associates and joint ventures for the quarter ended 31ST DECEMBER, 2021 and for the period from 1st April, 2021 to 31ST DECEMBER, 2021 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31th March 2021 and the corresponding period 01.04.2020 to 31.03.2021, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the

1) Sakar Oncology Private Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in



accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.L.Thakkar & Co
Chartered Accountants
FRN 120116W



Sanjiv Shah
Partner
Membership No. : 042264
UDIN : 22042264AAUPKX9669



Date : 08.02.2022
Place : Ahmedabad